@article{49fc1c96bbb14af4be7a7fff5f0606fe,
title = "Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting",
keywords = "Anti-HIV Agents, Biomarkers, HIV, HIV Infections, HIV-1, Heterocyclic Compounds, 3-Ring, Humans, Inflammation, Interleukin-6, Lamivudine, Longitudinal Studies, Oxazines, Piperazines, Pyridones, Viral Load, dolutegravir, dual therapy, inflammation, inflammatory biomarkers, lamivudine, Anti-HIV Agents, Biomarkers, HIV, HIV Infections, HIV-1, Heterocyclic Compounds, 3-Ring, Humans, Inflammation, Interleukin-6, Lamivudine, Longitudinal Studies, Oxazines, Piperazines, Pyridones, Viral Load, dolutegravir, dual therapy, inflammation, inflammatory biomarkers, lamivudine",
author = "Francesca Lombardi and Simone Belmonti and Davide Moschese and Massimiliano Fabbiani and Alberto Borghetti and Arturo Ciccullo and Elena Visconti and {Di Giambenedetto}, Simona",
year = "2022",
doi = "10.1080/25787489.2022.2080625",
language = "English",
volume = "23",
pages = "28--36",
journal = "HIV RESEARCH & CLINICAL PRACTICE",
issn = "2578-7470",
publisher = "Philadelphia PA: Taylor & Francis Inc.",
}
